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ii. Abstract: 
 
 
Assessment of the effectiveness of Electronic Gatekeeping as a utilization 
management tool at Groote Schuur Hospital 
 
BACKGROUND: Utilization management ensures the appropriateness of laboratory testing by 
reducing the performance of tests which can be reasonably avoided with no adverse effects for the 
patient. Electronic gatekeeping, a utilization management tool, was introduced at Groote Schuur in 
2010. Criteria were based on the minimum retesting interval, healthcare location, level of experience 
and discipline of the requesting clinician and specific ICD-10 codes. 
METHODS: A retrospective observational study assessing the effectiveness of electronic gatekeeping 
at Groote Schuur Hospital (Cape Town, South Africa), by comparing the test request volumes by using 
absolute test numbers and pre-defined ratios in the year prior to gatekeeping, to the two years 
following implementation. A secondary aim is to apply selected ratios to the other national academic 
hospitals to determine the potential for cost saving.  
RESULTS: At the medical wards of Groote Schuur Hospital there was an overall decrease in number 
and cost of tests of 24% per inpatient day for 2011. The most dramatic difference in cost is seen for 
chloride (91%) followed by HbA1c (90%), FT3 (89%) and CRP (82%). The application of ratios to Groote 
Schuur Hospital show a decrease in 2011 in all ratios apart from PCT: FBC+WCC (0.003 vs 0.002) and 
Mg: Ca (0.86 vs 0.84). AST: ALT remained the same at 0.55. This suggests overall effectiveness of the 
eGK rules although there is ongoing panel requesting. If the GSH eGK rules were to be applied at all 
other national academic hospitals, it could translate into a potential cost saving of $13 411 873.96 
(R103 196 838.80) per annum. 
 
CONCLUSIONS: Electronic gatekeeping is an effective utilization management tool at Groote Schuur 
Hospital. It is relatively easy to implement and manage, and when combined with additional tools has 
the potential to result in larger reductions of unnecessary tests, cost savings and improved patient 
outcome. 
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vii. Chapter 1: Introduction and literature review 
 
Laboratory medicine is faced with continual pressure to improve standards of healthcare whilst 
simultaneously removing inefficiencies and reducing cost (1). Commonly cited statistics report that 
70-80% of decisions affecting diagnosis or treatment are influenced by laboratory investigations (2, 
3); and that 25-30% of all requests are inappropriate (1). It is further estimated that laboratory 
workload increases by 10% each year without a corresponding increase in funding or staffing (4). 
The healthcare expenditure must be viewed within the context of the specific healthcare system. In 
2012 the UK NHS spent £2.5 billion on pathology investigations which was 4% of the total NHS 
expenditure of £106 billion (2, 3). The USA, with a fundamentally different healthcare system, 
spends approximately five times more (5) with an estimated 4-5 billion tests per annum at a cost of 
US$ 4 billion (6, 7). In South Africa 3.5% of the provincial budget is directed towards pathology 
services in the public sector. In the 2011/2012 budget, R121 billion was spent on healthcare with 
pathology services costing R4.2 billion (8). The Carter Report, a UK Department of Health 
commissioned review, stated that 20% (£500 million) can be saved by more efficient use of 
laboratory services. Extrapolating these figures to South Africa this equates to approximately R800 
million in potential savings (1, 3, 8). 
Utilisation/demand management: 
Utilisation or demand management aims to ensure the appropriateness of laboratory test 
requesting. It not only aims to reduce the volume of requests (demand control) but contains a 
quality aspect which may therefore result in an increase or decrease in testing (1).  
Importance of utilisation management: 
The importance of utilisation management lies in the fact that although laboratory testing forms a 
small part of healthcare expenditure, it often results in costly downstream care and investigations, 
the magnitude of which is difficult to estimate but is likely to be substantial (2, 9).  
Laboratory testing is influenced by patient-, doctor-, and policy or organisation-related factors (10). 
Utilisation management goes hand in hand with what is considered appropriate. A proposed 
definition is those tests that could reasonably be avoided with no significant detriment to patient 
care (5). The definition is challenging as there are no evidence-based standards to refer to, and what 
is appropriate is subject to the clinical context of the patient (11). 
Inappropriate requesting is widespread. Van Walraven and Naylor’s systematic review estimated 15-
56% variability between centres and practices (5). The reasons for this variability include differences 
in clinical practice and uptake of scientific guidelines, confirmed by Smellie when assessing 
requesting practices in general practice in the UK (12-14). Inappropriate requesting may apply to 
overutilization or underutilisation and to initial and repeat requests. Overutilization/over requesting 
applies to tests that are requested with no indication. Underutilisation refers to tests that are 
indicated but not requested (7). A 15-year systematic review found an overall rate of inappropriate 
overutilization of 20.6% (43.9% initial and 7.4% repeat) and a mean rate of inappropriate 
underutilisation of 44.8% (7).  
Outcomes of inappropriate laboratory tests may be obvious such as a waste of financial resources. 
The second and perhaps more important is the impact it has on the patient. It may have no impact, a 
negative impact or simply a noneconomic impact (9). An inappropriate request with no impact 
occurs with redundant testing, such as inadvertent repeats. There is no benefit or harm for the 
7 | P a g e  
 
patient but there is a negative financial impact (9). A negative impact occurs when the testing 
triggers a “Ulysses syndrome” when false positive test results lead to expensive and potentially 
dangerous diagnostic workups (9). Negative impacts for the patient include unnecessary discomfort, 
iatrogenic anaemia (13), vascular and nerve injury, introduction and spread of infection (15) and 
morbidity due to delayed or missed diagnosis due to underutilisation (7). 
Reasons for inappropriate requesting: 
Inappropriate requesting can arise from the laboratory; the requestor; the patient; or from a 
broader policy context (1, 2).  
Laboratory: This may occur with reflex testing, poor turnaround time of results or inadequate 
repertoire review (1). 
Requestor: There are several thousand commercially available laboratory tests with constant 
availability of new tests and methods (9). Requestors may be inexperienced (13) or succumb to 
patient and peer pressure (1). The convenience aspect such as the presence of an arterial line in situ 
(15) may also lead to increased testing. Many requestors are unaware of the test indications and 
costs, the recommended retesting intervals and may overestimate accuracy. Many report 
uncertainty about result interpretation (1, 2, 9) and formal training regarding appropriate utilisation 
is generally inadequate (13). Requestors may also practice defensively although in truth the failure 
to follow-up a result, or the misinterpretation thereof is a more common cause for medical 
malpractice litigation than faulty data gathering  (1, 9, 13).  
Patient: Patients may be unwilling to return for phlebotomy which results in testing to accommodate 
them (1, 15). Patients are the advocates of their own health and may expect blood tests to be 
performed following internet searches with little appreciation for the limitations of testing (2, 4, 16).  
Systemic (broader policy context): Duplicate test requesting may occur with a breakdown in 
communication between sites resulting in requestors being unable to access previous results (1, 5).  
Utilisation management interventions: 
The reasons for test requesting are complex and therefore behaviour modification initiatives are 
unlikely to be effective if single strategies are used or if the underlying barriers to behaviour change 
are not targeted (10, 17).  
Interventions can be divided into two categories: within-laboratory and pre-laboratory(1). 
Laboratory-based interventions may reduce inappropriate requests but do not have a patient focus. 
They do not prevent unnecessary phlebotomy, loss of work days or the expense of attending 
hospital (1, 18). 
Within-laboratory:  
Measures include repertoire review, vetting and within-laboratory alteration of requests, 
assessment of duplicate requests and retest intervals, gatekeeping and appending information to 
reports. 
Repertoire review: The test repertoire should constantly be reviewed to meet needs and respond to 
new developments. It may not change the volume of testing but is reported to improve turnaround 
time (1).  
Vetting and within-laboratory alteration of requests: High cost and low volume test numbers can be 
reduced. A large review of laboratory testing patterns found that low volume tests (ordered at least 
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10 times less frequently) are associated with a 3 times greater number of inappropriate requests 
(17). 
Laboratories may alter test requests internally using reflex or reflective testing protocols. This 
concept was demonstrated to improve the appropriateness of test requesting in 1988 by Finn et al  
(1). Diagnostic investigations beginning with cheap, sensitive, non-specific tests followed by 
predefined specific tests without input from the requestor is known as reflex testing. It can be 
complemented by reflective testing where laboratory professionals add tests based on the result 
and clinical information (19).  
Some authors feel it is not justifiable to cancel a requested test without consultation and the way to 
circumvent this is to require that certain test requests be justified before they are fulfilled (19). A 
straightforward method is telephonic or email contact with the requestor. This method is not 
feasible as it is labour intensive and disruptive to both the laboratory and requestor (19). 
Assessment of duplicate requests and retest intervals: Minimum retest intervals (MRIs) are 
established using published guidelines, analyte half-life and reference change values. These intervals 
can then be used to identify duplicate requests to which automatic rejection or individual vetting 
can then be applied (1). MRIs can be applied universally or to selected requestors and locations (1). 
Tyrrell et al achieved overall reduction in total requesting activity of 22.7% with MRIs (20). With 
Computerised Provider Order Entry systems(CPOE), the request may be prevented prior to 
phlebotomy (1) which is the ideal scenario. The association for clinical biochemistry (ACB) has a 
national minimum retesting interval project which provides a set of consensus/evidence-based 
recommendations (4). 
Selective limitations on test requesting: Some laboratories may establish criteria by which certain 
test requests will only be performed with pathologist approval (9). Others limit requests based on 
specialty or staffing grade (1). In Hutton’s study assessing CRP requesting patterns, the 
implementation of consultant-only requesting resulted in an overall reduction of 85% (21). This is 
however difficult to enforce and monitor (1). 
A seldom used strategy is that of rationing. Dixon et al noted that only 5% of laboratory results 
influenced patient management. They performed a study where laboratory test requesting was 
limited patients to 8 tests per day. The number of tests ordered decreased by two-thirds and the 
percentage of tests that influenced management went from 5 to 23% (22). This strategy threatens 
clinician autonomy however (13) and there must be measures in place to circumvent the limit (22). 
Gating test activity (gatekeeping): Setting criteria whereby tests will not be performed if a request 
reaches the laboratory is an attractive way of limiting overtly inappropriate requests. The most 
obvious examples are for frequent repetition of monitoring tests or duplication of investigations. It 
may be argued that duplication of a test or repetition within a short time is not necessarily 
inappropriate (5) and there must be a way in which to deviate from the policy (10). It may also be 
argued that gatekeeping must be restricted to inappropriate utilisation as it is counterproductive to 
harass requestors by imposing excessive obstacles to requesting (23).  
Two local retrospective studies assessed electronic gatekeeping on high volume chemistry tests. 
Smit et al noted that 6.7% of tests were rejected of which 14.7% were restored. They concluded that 
patient care was unaffected in 80% with a cost saving of £25,387 (24). Pema et al reported savings of 
$84,380 which was not felt to be as dramatic as expected (25). 
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A study assessing the requesting of ANCA showed that a gating policy which refused analysis not 
supported by clinical data made clinicians more selective (26). A study at the Feinberg School of 
Medicine used a combination of education and gatekeeping.  Tests costing more than $500 required 
approval by the laboratory medical director. They evaluated a paraneoplastic panel costing $1757.50 
with a turnaround time of 14-21 days. 9 of the 15 requests were cancelled, in discussion with the 
requestor, saving $15817.50 (27). 
Reducing the availability of on-site testing: In this instance, testing is available at certain times only, 
by offering a selected testing package outside office hours and during holiday periods (19). 
Pre-laboratory: 
Pre-laboratory interventions include education, request form design, the use of profiles and test 
combinations, financial incentives and penalties, and the use of information technology to support 
decisions.   
Education: In the review by Solomon et al, educational interventions were present in most of the 
successful studies identified (10). Education may be verbal, written or electronic (1); it can be active 
or passive (9); pulled (in response to a request) or pushed (unsolicited) (9).  
Pulled education is provided by pathologists and clinical scientists who are available to respond to 
clinical queries. This approach would be more efficient when provided in an easily accessible format 
such as a website. In this way, test requesting can be linked to online test directories when using 
CPOE (9).  
Pushed education can be provided at the time of request using CPOE, or through laboratory reports. 
An intensive approach is the provision of written materials as well as face-to-face interactions 
between requestor and the laboratory in a manner similar to pharmaceutical or medical device sales 
(9). 
Solomon et al noted that educational approaches were most successful when interventions targeted 
multiple behavioural factors (1), confirmed by Greco and Eisenberg’s 1993 study (10). Active 
education has also been found to be more effective, yet passive methods remain the most 
widespread (9).  
An important form of education is the use of feedback and reminders. Verstappen et al used 
education with personalised graphical feedback including a comparison of each physician’s own data 
with those of colleagues resulting in a 16% reduction of inappropriate tests (2). Thomas et al 
performed a study using quarterly feedback of requesting rates and reminder messages. The 
feedback included a booklet containing graphical presentations of individual practice ordering for 
targeted tests. Educational reminders were developed in conjunction with the physicians and were 
included with test results. They noted a 11% reduction in requests for practices receiving enhanced 
feedback or reminder messages and a combined reduction of 22% in total number of targeted tests 
ordered (2). Elnenaei et al’s study provided written feedback and evidence-based highlights to 
clinicians identified as having substantially higher requests. The outcome was an overall reduction of 
50% in the number of tests (28). Baker et al used guidelines followed by feedback for thyroid 
function tests, rheumatoid factor and urine cultures. They noted no effect, and this may be a 
function of how often and the way it is provided. Individualised feedback has been shown to be 
more effective than general feedback, in particular when it is regular, repeated and timely (2). Senior 
colleagues may also review the testing practices of junior colleagues in order to provide them with 
feedback (22). 
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Guideline education: Guidelines on test requesting are often aimed at the laboratory instead of 
requestors and when included in general guidelines the information may be hidden amongst 
management and treatment instructions (1). A study by Driskell et al assessed the appropriateness 
of HbA1c requests. They found that 49% of requests conformed to guidance despite guidelines on 
testing frequency being available from the ADA, NICE and Canadian diabetes association. This led to 
the conclusion that the publication of guidance had no significant impact on under/over requesting 
rates (3) and it has been noted elsewhere that guidelines alone are the least productive way of 
effecting change (5). Tomlin et al used a combination of guidelines, education and feedback for ESR 
requests and noted a 60% reduction in the number of requests (2). Guidelines need to be specific in 
order to be of positive use (10).  
Face-to-face sessions: in an approach referred to as academic detailing, written materials are 
provided as well as interactions with clinicians in a manner similar to pharmaceutical or medical 
device sales. This is intensive and costly and the expense may exceed potential savings (9). Barrichi 
et al designed pathology-specific algorithms for 7 common clinical scenarios and educated 
physicians about their use over eight training sessions. This intervention resulted in a 5% reduction 
in volume of tests requested. Larsson et al educated primary care physicians using a 2-day lecture 
series. Each participant received a folder containing information relating to the guidelines for future 
reference. They noted significant changes for 9/14 tests (2). 
Information technology and decision support: The ideal solution would be to provide information 
about best practice in real time using software systems which allow prompting at the point of 
request through the use of simple logic rules of web browser technology (5). A 2001 study by Van 
Wijk et al compared a guideline-based order form with a restricted guideline-based electronic order 
form. The group using the guideline-based form requested 20% fewer tests on average (2, 10).   
Test-report-based education: A concise footnote may be added to clarify the indications of a test, 
and the recommended follow-up testing and repeat interval. Salinas et al performed a study in 
which all requests for 1,25OHD were replaced by 25OHD and a comment as to the clinical utility was 
added. They noted that the requests for 25OHD increased with a corresponding decrease in 
1,25OHD requests (29). Education can also be provided at the time of request when computer order 
entry is used (9) although it has been reported that these methods only affect behaviour to a 
moderate extent (1). 
Request form design: The interface between the clinician and the laboratory is the request form, 
whether electronic or paper-based (13). The form or electronic order menu can be redesigned to 
reorganise tests, remove a test or replace with a better alternative. Cost information can also be 
displayed (9).  
Removal of a test from the request form is usually based on consensus expert opinion as there is 
usually no high-level evidence (10). In the review by van Walraven et al, urea requests decreased by 
57%, ESR requests decreased 58% and TSH requests decreased by 12% when removed from request 
form (30). Shalev et al reported a 27% reduction in deleted tests after removing 27 tests and adding 
2 (2). Zaat et al changed the request form to list 15 tests. They noted a 18% reduction in number of 
tests requested monthly (2). Bailey noted a 60-80% reduction when removing certain analytes from 
profiles (10). Yeh et al states that removal of the test from “quick-pick” order screens resulted in an 
immediate decrease of 50% (13). Seppanen et al removed ESR and AST from their computerised 
laboratory test order form resulting in a 90% decrease in their use (31). 
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Emerson et al changed the listing order leading to significant changes in utilization. Wong et al 
grouped thyroid function studies by clinical status which resulted in a 62% reduction in inappropriate 
tests(13, 22). 
Display of cost information: Horn et al displayed real-time cost information at the time of ordering. 
The change was dependent on the specifics of the test with reductions in higher cost tests in only 1 
of 6 tests (2). The success of this method is limited by the fact that many tests are requested 
because of clinically absolute reasons which are not affected by cost (1). 
Profiles and test combinations: The list of tests on a request form may be numerous and the use of 
test profiles can simplify the requesting process. These profiles are usually organ-based (1) with the 
advantage that investigation protocols are tailored to a diagnosis (5). There is generally considerable 
variation in profiles and not all tests are specific to the organ system in question. The National 
Pathology Benchmarking Service (UK) demonstrated 12 different profiles for ‘liver function test’ for 
example (1).  
The problem with organ-based profiles is that patients may present with nonspecific symptoms and 
investigation may span different organ systems. Additionally profile-based testing results in 
inappropriate tests when used for monitoring (1). Admission profiles may be used to ensure that 
important tests are not omitted. They may also reduce inappropriate requests being added (1).  
Financial incentives and penalties: The United States model uses a fixed tariff to physicians based on 
an episode of care (1).  Purely financial mechanisms could be detrimental to overall health-care 
provision as they potentially undermine quality, offering no rational system to ensure appropriate 
changes in requesting (10). Modest financial rewards at the provider level are not consistently 
effective and larger rewards run the risk for conflicts of interest for patient well-being (13).  
Spitzer reported that 50% of all laboratory requests are made without considering cost (22) however 
in van Walraven’s study, when a medical plan stopped funding T4 testing, requests decreased by 
96% (30). 
Information technology and decision support: Electronic medical record systems allow for viewing of 
laboratory results and some allow for online test requesting. Information technology systems may 
influence requesting by making historic results easier to view at the time of request, and so reduce 
repeat orders. CPOE may be linked to feedback and decision support systems (9). Pop-up reminders 
of redundant or outmoded tests may be used to educate ordering physicians as long as they are not 
too intrusive (13). Young et al noted that decision support systems require significant technical 
support and medical supervision to keep protocols up to date (22).  
 
Conclusion: 
Inappropriate testing is widespread with large variation noted between different institutions and 
practices. Utilisation management is a way of decreasing the number of inappropriate requests, 
whether this results in increased or decreased testing, and improving patient outcomes.  
There are several different utilisation management strategies however the most effective 
approaches are those that target multiple behavioural factors.  
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viii. Chapter 2: Publication-ready manuscript 
 
Laboratory medicine is faced with continual pressure to improve standards of healthcare whilst 
simultaneously removing inefficiencies and reducing costs (1). Laboratory investigations influence 
70-80% of healthcare decisions (2, 3)  with 25-30% of all requests being inappropriate (1). In the 
2011/2012 South African national budget, R121 billion was spent on healthcare with 3.5% of the 
provincial budget directed towards pathology services in the public sector at a cost of R4.2 billion 
(4). The Carter Report, a UK Department of Health commissioned review stated that 20% (£500 
million) can be saved by more efficient use of laboratory services in the National Health Service 
(NHS). Extrapolating these figures to South Africa, this equates to approximately R800 million in 
potential savings (1, 3, 4). 
Utilization or demand management is a means by which the appropriateness of laboratory test 
requesting is ensured (1). A proposed definition is those tests that could reasonably be avoided with 
no significant detriment to patient care (5).  
Inappropriate requesting is widespread with an estimated 15-56% variability between practitioners 
and centres (5). Potential explanations offered are differences in clinical practice and either the lack 
of established scientific guidelines or differences in the application thereof (6-8).  
Inappropriate requesting may lead to overutilization or underutilization and may apply to initial and 
repeat requests (9).  It can arise from the laboratory (reflex testing, poor turnaround time of results, 
inadequate repertoire review) (1); from the requestor (inexperience (10), inability to select 
appropriately from  the large number of commercially available tests (8), patient or peer pressure 
(1), lack of awareness of indications, cost, recommended retesting intervals (11), convenience 
testing in a busy practice, and the practice of defensive medicine (1, 8)); and from the patient who 
may be unwilling to return for phlebotomy (1, 10). Patients are increasingly becoming the advocates 
of their own health and may expect blood tests to be performed following internet searches with 
little appreciation for the limitations of testing (11-13). A systemic reason may be a breakdown in 
communication between sites resulting in duplicate testing (1, 5).  
The obvious outcome of an inappropriate laboratory request is a waste of financial resources. 
Secondly and perhaps more importantly is the impact it may have on the patient. Negative impacts 
as a result of overutilization occur when testing triggers potentially expensive and dangerous 
diagnostic workups and therapies following false positive results (14). Additional negative impacts 
include unnecessary discomfort, iatrogenic anaemia (7), vascular and nerve injury and introduction 
and spread of infection (10). A negative impact associated with underutilization is increased 
morbidity due to delayed or missed diagnoses (9). 
Interventions can be divided into two categories: pre-laboratory and within-laboratory (1). Pre-
laboratory interventions include education, request form design including the display of cost per 
test, unbundling of tests, discouraging the use of profiles, and the use of information technology to 
support decisions (15).  Laboratory-based interventions may reduce inappropriate requests but lack 
a patient focus (1, 16). These include repertoire review, vetting, within-laboratory alteration of 
requests, preventing duplicate requests, minimum retest intervals (MRIs), gatekeeping and 
appending information to reports. Tyrrell et al achieved overall reduction in total requesting activity 
of 22.7% with MRIs (17). Additionally, laboratories may establish criteria by which certain test 
requests will only be performed with pathologist approval (14), or limit requests based on specialty 
(1). In Hutton’s study assessing C-reactive protein (CRP) requesting patterns, the implementation of 
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consultant-only requesting resulted in an overall reduction of 85% (18). This is however difficult to 
enforce and monitor as clinicians may resort to using the names of colleagues for restricted tests (1). 
Gatekeeping is a utilization management tool whereby clinical and logical criteria are determined for 
the appropriate use of specific tests. If any parameter falls outside of the criteria the test is rejected. 
This is most obviously applied to repetition or duplication of investigations (5). Two local 
retrospective studies assessed electronic gatekeeping on high volume chemistry tests. Smit et al 
noted that 6.7% of tests were rejected of which 14.7% were subsequently restored. They concluded 
that patient care was unaffected in 80% of cases with a cost saving of £25,387 over the 6-month 
study period (19). Pema et al reported savings of $84,380 over a 22 month period with the most 
notable savings in glycated haemoglobin (HbA1c), thyroid stimulating hormone (TSH) and urea (20). 
At Groote Schuur Hospital (GSH) test utilization practice changes were introduced in 2009, when test 
request protocols for various targeted analytes (CRP, free thyroxine (fT4) and HbA1c) were 
developed in consultation with a clinical team of senior clinicians. At this time the expectation was 
that there would be voluntary compliance after education. The test costs were also added to the 
request form at the time, as per the request of the National Department of Health.  
In January 2010, following poor compliance, manual gatekeeping was enforced by a hospital 
appointed laboratory gatekeeper. This process entailed manual checking of request forms which was 
labour-intensive, delayed test turn-around time and provided limited scope.  
In September 2010, electronic gatekeeping was introduced for a larger scope of analytes. High 
volume and high cost tests (urea, creatinine, liver functions, CRP, HbA1c, thyroid function tests, full 
blood count, CD4 and HIV viral load) were targeted. A system of authorisation numbers was 
instituted to prevent rejection or to allow the restoration of tests. These numbers were managed by 
the medical superintendent and implemented by the laboratory. Gatekeeping criteria were based on 
the minimum retesting interval, the level of healthcare (location), the level of experience and 
discipline of the requesting clinician and specific ICD-10 codes (Table 1). The implementation of 
electronic gatekeeping at Groote Schuur formed part of a pilot project in the Western Cape. 
The aim of this study was to assess the effectiveness of electronic gatekeeping at Groote Schuur 
Hospital by comparing the test request volumes and cost per inpatient day in the year prior to the 
implementation of gatekeeping, to the two years following the implementation of electronic 
gatekeeping. In addition, the test request volumes of tests subject to gatekeeping was compared to 
tests without gatekeeping.  
A secondary aim was to determine the potential cost saving if the same criteria were applied across 
the other national academic hospitals by means of selected ratios. 
This is the first study of this kind to be performed at Groote Schuur Hospital and the first study 
assessing potential national cost savings in South Africa. 
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Group Test MRI Restriction (Minimum Retest Interval) Other restriction Unrestricted Use in profiles 
Metabolic tests Sodium   No eGK 
restrictions 
“UEC” profile 
discouraged  Potassium   No eGK 
restrictions 
“UEC” profile 
discouraged  Chloride  Specialist only  Not in “UEC” profile 
 Urea Inpatient: 24 hours; Outpatient: 2 weeks   “UEC” profile 
discouraged  Creatinine Inpatient: 24 hours; Outpatient: 2 weeks   “UEC” profile 
discouraged Liver function tests: Total protein 1 month   Not in “LFT” profile 
 Albumin   No eGK 
restrictions 
Not in “LFT” profile 
 Total bilirubin Inpatient: 2 days; Outpatient: 1 week    
 Direct bilirubin 1 week   Not in “LFT” profile 
 ALT Inpatient: 2 days; Outpatient: 1 week    
 AST Inpatient: 2 days; Outpatient: 1 week   Not in “LFT” profile 
 ALP Inpatient: 2 days; Outpatient: 1 week    
 GGT Inpatient: 2 days; Outpatient: 1wk   Not in “LFT” profile 
Infection markers: CRP ID / Rheum wards only: Repeat within I week            
Rest of wards: No repeat unless previous result 
abnormal 
  
 PCT   No eGK 
restrictions 
 
 FBC Inpatient: 24 hours; Outpatient: 4 weeks    
 WCC   No eGK 
restrictions 
 
Glycaemic control: HbA1c Obstetric/Diabetic: 1 month 
Other wards: 6 months 
Other wards: No first-time requests    
 Glucose   No eGK 
restrictions 
 
Thyroid function 
tests: 
TSH 3months    
 Free T4 No MRI. FT4 added when TSH abnormal   Not in “TFT” profile 
 Free T3 No MRI. Selected specialists only  Not in “TFT” profile 
 Ca No MRI.   “CMP” profile 
discouraged  Mg  Selected specialists only  “CMP” profile 
discouraged  Phos No MRI.   “CMP” profile 
discouraged Table 1. Electronic gatekeeping criteria implemented at Groote Schuur Hospital in 2010 (see Abbreviations in section iv)
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Methods: 
STUDY DESIGN: The study is a retrospective observational study. 
DATA COLLECTION: The subjects are Groote Schuur Hospital (Cape Town, Western Cape) and the 
other national South African academic hospitals, namely Charlotte Maxeke Hospital (Johannesburg, 
Gauteng), Chris Hani Baragwanath Hospital (Johannesburg, Gauteng), Dr George Mukhari Hospital 
(Pretoria, Gauteng), Inkosi Albert Luthuli Central Hospital (Durban, Kwazulu-Natal), Mthatha Hospital 
(Mthatha, Eastern Cape), Tshwane Academic Hospital (Pretoria, Gauteng), Tygerberg Hospital (Cape 
Town, Western Cape) and Universitas Hospital (Bloemfontein, Free State).  
Data were extracted from the National Health Laboratory Services (NHLS) Laboratory Information 
System (LIS). The year 2008 was selected as the “pre-electronic gatekeeping” period. The years 2011 
and 2012 were selected as the “post-electronic gatekeeping” period. This allows an assessment to 
be made as to whether the change was sustained. Data was extracted for Groote Schuur Hospital 
(2008, 2011 and 2012) as well as the other tertiary academic hospitals in South Africa (2012). Groote 
Schuur Hospital provided data on the number of patient days for the medical wards.  
Data were collected for: C-reactive protein (CRP), glycated haemoglobin (HbA1c), procalcitonin 
(PCT), full blood count (FBC), white cell count (WCC), creatinine (Creat), urea, sodium (Na), 
potassium (K), chloride (Cl), calcium (Ca), magnesium (Mg), phosphate (Phos), thyroid stimulating 
hormone (TSH), free thyroxine (fT4), free triiodothyronine (fT3), liver function tests (LFT) comprising 
total protein (TP), albumin (Alb), total bilirubin (Tbili), direct bilirubin (Dbili), alanine transaminase 
(ALT) and aspartate transaminase (AST), and glucose.  
Outpatient clinics and surgical wards were excluded and data were limited to chemical pathology 
and occasional haematology tests.  
DATA ANALYSIS: Data analysis consisted of two components.  
Firstly, the number of tests processed from all adult medical inpatient wards at Groote Schuur 
Hospital were compared before and after the implementation of electronic gatekeeping. Adult 
medical wards were selected as a representative sample. The number of tests processed is 
expressed per inpatient day (a measure of hospital occupancy for the number of beds available), 
using the equation: inpatient days + (1/2 of Day patients))/Bed days / 975 (number of beds). This 
standardises for potential changes in patient numbers. This number was calculated and supplied by 
Groote Schuur Hospital management. The cost of testing was determined using the NHLS tariffs in 
2012/2013. 
Secondly, selected test ratios were used to assess the overall impact of electronic gatekeeping on 
test request patterns at Groote Schuur Hospital, pre- and post-electronic gatekeeping for the whole 
hospital (Table 2). The ratios were also applied to the other academic hospitals in South Africa to 
allow the formulation of a hypothesis as to the potential cost-saving if the same gatekeeping rules 
were to be applied nationally. The institution names are not listed for the remainder of the 
manuscript and are presented in a non-alphabetic but consistent order. To compare cost of testing, 
Groote Schuur was taken as the comparator and the ratios for tests performed at each of the 
academic hospitals (GSH 2012) were provided as multiples of the corresponding GSH ratio in 2012. 
The potential savings were calculated by subtracting the amount calculated using the ratio from the 
total number of tests performed per hospital in 2012. The savings were presented in South African 
Rand (ZAR) and US Dollar (USD), converted using an average of the ZAR-USD exchange rates from 
2008, 2011 and 2012 (1ZAR = 0,129964 USD) (21). 
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Ratio Rationale 
CRP: [FBC+WCC] FBC / WCC is requested routinely. If the ratio is ≥ 1 then this suggests 
inappropriate testing.  
FBC and WCC analysed together as WCC is often not requested alone. 
PCT: [FBC+WCC] This ratio assesses whether the PCT: [FBC / WCC] testing increased due to 
CRP gatekeeping. 
fT4: TSH With the implementation of gatekeeping any request for thyroid 
functions will result in a TSH being performed (with fT4 reflex testing 
when the result is abnormal). A ratio < 1 implies a decrease in fT4 testing 
which would suggest decrease in “Thyroid Profile” testing.  
fT3: TSH Free T3 is only allowed by specific requestors. The ratio indicates the 
effectiveness of gatekeeping. A ratio < 1 suggests decreased “Thyroid 
Profile” testing. 
fT3: fT4 Free T3 should be performed when the patient is on T3 therapy or when 
the TSH and fT4 results are not well explained. This ratio should be < 1 
and indicates whether testing is being performed appropriately. 
AST: ALT This ratio indicates whether fewer full LFT panels were performed. When 
“LFT” is requested then Alb, Tbili, ALT, and ALP are performed. AST is 
performed only when specifically selected. Since ALT is more liver-
specific, a decreased ratio implies a decrease in inappropriate requesting. 
TP: ALT Frequent testing of total protein testing is inappropriate since a clinically 
significant change cannot be interpreted without albumin testing.  
The ratio will also assess the decrease in the number of full LFT panels 
performed after implementation of gatekeeping. 
urea: creatinine Before gatekeeping the request for urea + creatinine would have resulted 
in testing of both analytes. After gatekeeping, such a request would 
result in only creatinine being performed instead. 
chloride: sodium Chloride is subjected to electronic gatekeeping. The ratio will reflect 
whether eGK resulted in a decrease in UEC panel testing. Sodium 
requesting is not restricted. 
HbA1c: Creatinine Urea, electrolytes and creatinine are performed routinely, mainly in 
diabetic patients. This ratio assesses whether HbA1c is also performed in 
a routine manner. 
Mg: Ca Magnesium testing only performed on consultant request. This ratio 
assesses whether gatekeeping affected the number of calcium, 
magnesium and phosphate (CMP) panel requests.  
Table 2. Ratios for comparison of GSH (Pre and Post-eGK) and GSH with other national hospitals (see Subject Selection in 
Methods) 
 
ETHICS: The study was approved by the Health Research ethics committee of the Faculty of Health 
Sciences University of Cape Town. The data is retrospective and anonymous with no individual 
patient results or identifiers. Informed consent was not required. 
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Results: 
Change in request patterns in GSH: 
The number of tests performed per inpatient day in the medical wards was compared for the 
assessment periods of 2008, pre-electronic gatekeeping (eGK) and 2011, post-eGK. Table 3 
demonstrates the absolute changes in number and cost per test per inpatient day. 
 
Analyte 2008 2011 Change 
 Tests per 
inpatient day 
Cost per 
inpatient day 
Tests per 
inpatient day 
Cost per 
inpatient day 
Tests per 
inpatient day 
Cost per 
inpatient day 
Sodium 0.21 R5.55 0.25 R6.57 0.04 R1.02 
Potassium 0.21 R5.55 0.26 R6.91 0.05 R1.36 
Chloride 0.05 R0.91 0.004 R0.08 -0.04 R-0.83 
Urea 0.21 R5.56 0.24 R6.21 0.02 R0.65 
Creatinine 0.22 R5.72 0.26 R6.90 0.04 R1.18 
Total protein 0.09 R2.07 0.02 R0.47 -0.07 R-1.60 
Albumin 0.12 R4.05 0.06 R2.01 -0.06 R-2.04 
Total bilirubin 0.12 R3.59 0.06 R1.92 -0.05 R-1.67 
Direct bilirubin 0.10 R2.36 0.03 R0.79 -0.07 R-1.56 
ALT 0.13 R4.94 0.08 R3.09 -0.05 R-1.85 
AST 0.11 R4.46 0.06 R2.36 -0.05 R-2.10 
ALP 0.12 R4.62 0.06 R2.38 -0.06 R-2.24 
GGT 0.11 R4.52 0.06 R2.27 -0.06 R-2.26 
CRP 0.04 R3.17 0.01 R0.56 -0.03 R-2.61 
PCT 0.01 R1.71 0.002 R0.70 -0.003 R-1.01 
FBC 0.19 R9.45 0.18 R9.21 -0.005 R-0.24 
WCC 0.01 R0.18 0.01 R0.18 -0.0002 R-0.003 
HbA1c 0.003 R0.26 0.0004 R0.03 -0.003 R-0.23 
Glucose 0.012 R0.33 0.004 R0.22 -0.01 R-0.22 
TSH 0.01 R1.88 0.01 R1.19 -0.005 R-0.69 
Free T4 0.01 R1.15 0.003 R0.35 -0.01 R-0.80 
Free T3 0.002 R0.29 0.0002 R0.03 -0.002 R-0.26 
Ca 0.05 R1.26 0.05 R1.26 0.0002 R0.01 
Mg 0.04 R1.14 0.05 R1.19 0.002 R0.05 
Phos 0.04 R1.13 0.04 R1.13 -0.0002 R-0.004 
Table 3. Absolute changes in number and costs of tests performed per inpatient day. (-) indicates a decrease in cost. The cost is 
calculated using NHLS tariffs from 2012/2013. 
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Decreases in testing were seen for Cl, TP, CRP, HbA1c, fT4, fT3, Alb, Tbili and Dbili, ALT, AST, ALP, 
GGT, FBC, TSH, Gluc and PCT.  
Testing increased for urea, Creat, Na and K while remaining unchanged for WCC, Ca, Mg and Phos. 
Testing patterns between 2011 and 2012 are similar when compared to 2008 (see supplementary – 
Table 1). 
 
Cost savings achieved at GSH following EGK: 
 
Figure 1. % Cost-saving after eGK implementation at Groote Schuur Hospital (2011). Negative values refer to cost increases. 
Figure 1 represents the % cost-saving per inpatient day in 2011 when compared to 2008. There was 
an overall decrease in cost of 24% per inpatient day.  
The most dramatic difference was seen for chloride (91% - R0.91 to R0.08 per test per inpatient day) 
followed by HbA1c (90% - R0.26 to R0.03), FT3 (89% - R0.29 to R0.03) and CRP (82% - R3.17 to 
R0.56). The difference in cost of R2.61 for CRP is the biggest monetary saving. 
White cell count showed the smallest cost-saving (2%).  There was no cost-saving for calcium and 
phosphate. Magnesium cost increased by 4%, urea by 12% and creatinine by 21%, despite 
gatekeeping.   
Sodium and potassium were not subject to electronic gatekeeping. The cost per test increased by 
18% and 25% respectively.    
Tests with the highest cost per inpatient day are: FBC (R9.45), Creatinine (R5.72) and Urea (R5.56). 
Following the implementation of gatekeeping the cost for FBC decreased to R9.21. Creatinine 
increased to R6.90 (21%) and urea to R6.21 (12%).  
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Test ratio changes within GSH after EGK (Figure 2): 
The following ratios demonstrated a decrease (2011 vs 2008): CRP: FBC+WCC (0.07 vs 0.15), fT4: TSH 
(0.43 vs 0.60), fT3: TSH (0.04 vs 0.14), urea: creatinine (0.63 vs 0.88), HBA1c: creatinine (0.04 vs 
0.06), Cl: Na (0.11 vs 0.32) and TP: ALT (0.21 vs 0.30). 
In contrast, PCT: FBC+WCC demonstrated an increase (0.003 vs 0.002) as did Mg: Ca (0.86 vs 0.84). 
AST: ALT remained the same (0.55). 
 
 
Figure 2. The ratios of analytes tested at Groote Schuur Hospital 2008 vs 2011. 
 
Test ratio comparison between GSH and other academic hospitals in South Africa: 
To compare the cost of testing, Groote Schuur was taken as the comparator with an assigned value 
of 1.0 and the testing pattern for the academic hospitals are provided as multiples of the GSH ratio 
(Table 4 and supplement Table 3). A ratio of 1 would therefore suggest that testing patterns are the 
same as those at GSH.  
Table 4 (Table 2 supplement) demonstrates that the majority of hospitals had ratios that were higher 
than those at GSH. 
Hospital 10 performed 6.50 times more CRP testing than GSH. Hospital 9 and 8 performed 6.1 and 
5.6 times more respectively. The GSH gatekeeping rules at hospital 10 would result in an annual cost 
saving of $317 313.90 (R244 1552) just for CRP. When implemented at all academic hospitals the 
national annual savings would approach $2 870 347 (R22 08 5707).  
Hospital 10 also performed significantly more PCT tests (93.4), followed by hospital 9 (43.4) and 6 
(32.8). National annual savings for this test would be approximately $3 224 952 (R24 814 195). 
Chloride testing was performed 8.8 times more by hospitals 2, 3, 6 and 8. By applying the 
gatekeeping criteria implemented at GSH the potential national cost saving would be $1 955 233 
(R15 044 418). 
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Urea testing was performed in a similar way across all hospitals. Hospitals 6 and 10 (1.6 times more) 
and hospital 2 (1.5 time more). Potential cost savings amount to $983 507.70 (R7 567 539). 
AST testing was performed less by Hospitals 2 and 5. The remainder performed similarly to GSH. The 
national annual cost saving would amount to $382 118.30 (R2 940 186). 
Total protein testing was performed less by Hospitals 5 and 9. Hospital 6 performed 4.5 times more 
than GSH. Hospitals 2 and 3 performed 4.1 and 3.1 times more respectively. National annual savings 
of $624 880.10 (R4 808 102) can be expected. 
HbA1c was performed 8.3 times more than GSH. Hospital 8 performed 4.2 times more and hospital 
10 2.4 times more. Hospital 2 performed less HbA1c tests than GSH. Total national savings amount 
to $961 627.50 (R7 399 184). 
Free T4 testing was performed 2.4 times more by hospital 6, 2.2 times more than GSH by hospital 4 
and 2.1 times more than GSH by hospitals 3 and 10. Total national savings of $1 206 955 
(R9 286 843) could be expected for this test. Free T3 was performed by Hospitals 4, 6 and 3 more 
than 24.6, 19.3 and 15.3 times that of GSH. Total national saving of $1 106 740 (R8 515 743) can be 
expected with the GSH eGK rules. 
When comparing the FT3: FT4 ratio, hospitals 4, 6 and 3 performed 11.6, 9.3 and 8.7 times more 
than GSH. Hospitals 7 and 10 performed less testing compared to GSH. 
The Mg: Ca ratios were similar to the GSH ratio. Hospitals 5 and had ratios of 1.0 while the 
remainder had ratios of 1.1. 
The total cost saving potential with GSH eGK rules would possibly exceed $13 411 873.96 
(R103 196 838.80) per annum on a national scale. 
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 Ratio Absolute number of tests Cost USD Cost ZAR Cost-saving USD Cost-saving ZAR 
CRP: [FBC+WCC]   10.24 78.81 2 870 347 22 085 707 
Groote Schuur 0.08 (1.0) 14 542 148 945.90 1 146 055   
Hospital 10 6.5 36 613 375 007.30  2 885 471 317 313.90 2 441 552 
Hospital 9 6.1 48 542 497 189.60 3 825 595 420 698.90 3 237 042 
Hospital 8 5.6 81 402 833 757 6 415 292 684 871.80 5 269 704 
PCT: [FBC+WCC]   43.72 336.41 3 224 952  24 814 195 
Groote Schuur 0.004 (1.0) 790 34 539.70 265 763.90   
Hospital 10 93.4 25 919 1 133 210 8 719 411 1 121 072 8 626 019 
Hospital 9 43.4 15 734 687 909.20 5 293 075 672 067.80 5 171 184 
Hospital 6 32.8 15 080 659 315.50  5 073 063 639 219.80 4 918 438 
Cl: Na   2.44 18.75 1 955 233 15 044 418 
Groote Schuur 0.12 (1.0) 17 339 42 252.10 325 106.30   
Hospital 2 8.8 75 360 183 639.10  1 413 000 162 673.30 1 251 680 
Hospital 3 8.8 65 884  160 547.80 1 235 325 142 213.50 1 094 253 
Hospital 6 8.8 104 153    253 802.60 1 952 869 224 918.50 1 730 622 
Hospital 8 8.8 169 130 412 140.20 3 171 188 365 101.50 2 809 251 
Urea: Creat   3.41 26.27 983 507.70  7 567 539 
GSH 0.58 (1.0) 138 514 472 908.20 3 638 763   
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Hospital 6 1.6 104 307 356 120.20 2 740 145 139 363.20 1 072 321 
Hospital 10 1.6 82 490 281 633.60 2 167 012 108 631.80 835 861 
Hospital 2 1.5 75 766 258 676.80 1 990 373 84 812 652 580.80 
AST: ALT   5.11 39.34 382 118.30  2 940 186 
GSH 0.59 (1.0) 49 289 252 004 1 939 029   
Hospital 2 0.3 12 549 64 160.30 493 677.70   
Hospital 5 0.7 18 459 94 376.90 726 177.10   
Hospital 6 1.8 65 873 336 794.40 2 591 444 146 417.80 1 126 603 
Hospital 10 1.7 34 977 178 829.80 1 375 995 74 371.40 572 246.20 
TP: ALT   2.93 22.58 624 880.10  4 808 102 
GSH 0.24 (1.0) 19 714 57 852.45  445 142.10   
Hospital 6 4.5 65 556 192 379.80 1 480 254 149 770.30 1 152 398 
Hospital 2 4.1 53 733 157 684.20 1 213 291 119 239.50 917 481 
Hospital 3 3.1 33 133 97 231.70 748 143.10 65 394.65 503 175.20 
HbA1c: Creat   9.61 73.96 961 627.50 7 399 184 
GSH 0.04 (0.1) 8 851.61  85 077  654 620   
Hospital 6 8.3 41 992 403 632.90 3 105 728 97 621.20 2 731 733 
Hospital 8 4.2 37 514 360 589.70 2 774 535 58 363.60 2 108 734 
Hospital 10 2.4 8 225 79 059.80 608 321 11 588.20 349 974.10 
T4: TSH   16.60 127.75 1 206 955  9 286 843 
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GSH 0.38 (1.0) 9 597 159 338  1 226 017   
Hospital 6 2.4 70 982 1 178 507  9 067 951 676 086.20 5 202 104 
Hospital 4 2.2 11 008 182 764.70  1 406 272 99 829 768 128.50 
Hospital 3 2.1 3 059 50 788.27 390 787.30 26 371.65 202 915.10 
Hospital 10 2.1 16 760 278 264.60  2 141 090 146 586.70 1 127 903 
T3: TSH   16.60  127.75 1 106 740  8 515 743 
GSH 0.03 (1.0) 769 12 767.63 98 239.75   
Hospital 4 24.6 10 264 170 412.20  1 311 226 163 471.10 1 257 818 
Hospital 6 19.3 53 014 880 186.20  6 772 539 834 643.50 6 422 113 
Hospital 3 15.3 2 131 35 380.78 272 235.30 33 072.80 254 476.50 
T3: T4   16.60  127.75   
GSH 0.08 (1.0) 769     
Hospital 4 11.6 10 264     
Hospital 6 9.3 53 014     
Hospital 3 8.7 2 131     
Mg: Ca   3.41 26.27 95 513.44 734 922.30 
GSH 0.91 (1.0) 30 913 105 541.80  812 084.50   
Hospital 2 1.1 39 983 136 508.10 1 050 353 11 895.10 91 526 
Hospital 3 1.1 10 901 37 217.70 286 369.30 3 549.60 27 312.30 
Hospital 4 1.1 9 324 31 833.60 244 941.50 2 073.20 15 952 
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Hospital 5 1.0 40 593 138 590.80 1 066 378 3 381.90 26 021.50 
Hospital 6 1.1 49 505 169 017.70 1 300 496 18 881.70 145 284 
Hospital 7 1.1 70 340 240 151.60 1 847 832 18 816.20 144 780.30 
Hospital 8 1.1 86 313 294 685.90 2 267 443 21 046.30 161 939.80 
Hospital 9 1.0 38 658 131 984.40 38 658   
Hospital 10 1.1 38 745 132 281.40 1 017 831 15 869.40 122 106.30 
Total     13 411 873.96  103 196 838.80 
Table 4. Cost saving implications - Selected ratios of Groote Schuur Hospital and other national academic hospitals. Hospitals 2 – 10 are compared to GSH which is taken as the comparator 
with an assigned ratio of 1. Selective data displayed in this table (see supplement Table 3 for full data table). The total listed is for all hospitals.
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Discussion 
In this study we assessed the number and cost of tests processed pre- and post-implementation of 
electronic gatekeeping from medical inpatient wards at Groote Schuur Hospital (Cape Town, South 
Africa). The data was standardised by the calculation of inpatient days as well by using the same 
NHLS tariffs.  
The analytes subject to electronic gatekeeping using MRIs (total protein, total and direct bilirubin, 
AST, ALT, ALP, GGT, CRP, FBC, HbA1c and TSH) showed a decrease in testing volume. Of these the 
greatest was with HbA1c (90%) and CRP (82%) and the smallest with FBC (3%) and WCC (2%). This 
may suggest that these analytes were previously inappropriately repeated before this would be 
clinically useful.  
Although subject to gatekeeping with MRIs, urea and creatinine testing and cost increased by 12% 
and 21%. Sodium and potassium numbers and cost increased by 18% and 25% respectively. This may 
suggest that clinicians were still selecting the tests individually to bypass the attempt to discourage 
testing of the “UEC profile”. Other explanations include a change in clinical practice amongst 
clinicians at the hospital and a possible increase in patient turnover increasing the number of tests 
attributed to an inpatient day.   
Analytes subject to electronic gatekeeping by restricting use to certain specialists are chloride, free 
T3 and magnesium.  Decrease in testing is seen for chloride (91%) followed by FT3 (89%). The cost of 
magnesium testing increased by 4% despite the restriction and this may suggest that specialist codes 
were used by non-specialist clinicians to bypass the gatekeeping rule and request the “CMP” profile. 
Calcium and phosphate testing had no cost-saving. This explanation could also be applied to the Mg: 
Ca ratio which remained the same. 
Procalcitonin testing increased slightly and this might be explained by CRP gatekeeping although the 
volumes are not nearly comparable with the number previously requested for CRP.  
Overall, a 24% cost-saving was made at Groote Schuur Hospital per inpatient day. 
Ratios were used to compare testing at Groote Schuur Hospital in the pre- and post-eGK periods. All 
ratios showed a decrease in testing apart from PCT: FBC+WCC and Mg: Ca which demonstrated a 
demonstrated an increase. The AST: ALT ratio remained the same in contrast with TP: ALT for which 
a decrease was noted. The explanation may rest with the fact that liver function tests were 
restricted according to MRI and when a “LFT” panel was requested then albumin, ALT, ALP, and Tbili 
would be performed. The AST: ALT and TP:ALT ratios both assess the use of the LFT profile. This may 
suggest that AST was individually selected along with ALT when requesting this group of tests. Total 
protein testing is clinically useful when conditions causing an increase in immunoglobulins or a 
decrease in albumin are suspected. Generally, frequent repetition is not useful and the decrease in 
this ratio may imply effectiveness of gatekeeping. 
The ratios were also used to compare the other national academic hospitals with Groote Schuur by 
using GSH as the comparator. For the CRP: FBC+WCC ratio, hospital 10 had the highest ratio of 6.50. 
This ratio suggests that CRP was requested without FBC/WCC testing, which would be expected in a 
patient with a suspected infection.  Hospital 10 performed 93.4 times the number of PCT tests 
compared to GSH. The ratio appears very high due to the low number of PCT tests performed at GSH 
and the high number at hospital 10. PCT testing did not increase at GSH, even though it was not 
subject to eGK. A possible explanation for the increased testing at hospital 10 could be a paediatric 
ICU using PCT in an antibiotic stewardship program. For the Cl: Na ratio, the majority performed 8.8 
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times more chloride tests than GSH which implies increased “UEC” profile testing. Chloride testing is 
useful in clinical circumstances where the anion gap is to be calculated. Most clinical diagnoses will 
not be influenced by chloride. 
The HbA1c: Creat ratio for hospital 6 was 8.3 when compared to GSH. It is possible that glycated 
haemoglobin was tested more frequently than 3-monthly due to poor adherence to guidelines. Free 
thyroxine testing was comparable to GSH while hospitals 3, 4 and 6 performed 15, 24 and 19 times 
more FT3 respectively. The reflexive testing of fT4 when the TSH is abnormal would prevent this. 
Magnesium: Calcium (Mg: Ca) ratios were similar across the hospitals which likely indicates that CMP 
profile testing was still being frequently performed without indication. 
Recognised limitations of this study include the exclusion of outpatient clinics and surgical wards 
when calculating the number and costs per test per inpatient day. This would have resulted in 
exclusion of testing performed by the emergency department prior to admission. Tests were limited 
to chemical pathology and occasional haematology tests. We did not assess the change in clinician 
requesting behaviours after implementation of electronic gatekeeping or assess the number of tests 
rejected or reinstated. 
It is not possible from the data to extrapolate the total cost saving to each individual hospital budget 
or to assess an increase in workload. However, had the GSH eGK rules been implemented on a 
national scale there would have been a total cost saving of approximately $13 411 873.96 
(R103 196 838.80) per year for the national health budget. The study did not address patient 
outcomes.  
Electronic gatekeeping started in the Western Cape province at Groote Schuur Hospital and 
Tygerberg Hospital. Subsequent to this, eGK was implemented in Gauteng province and the Eastern 
Cape province, also using facility-specific rules. The variations in test criteria between hospitals 
created difficulty for the clinicians moving to and working in different facilities within these 
provinces. In 2016 the Department of Health (DoH) asked the NHLS to extend eGK to all facilities 
including Primary Health Care facilities. As there are over 5000 DoH facilities, writing facility-specific 
rules was not feasible. The NHLS expert committees proposed identical gatekeeping rules for non-
critical tests based on MRIs. This proposal was discussed with provincial DoH teams. The decision 
was made to program identical eGK rules for 60 tests, with the ability to program exceptions at 
facilities where necessary, particularly at academic facilities. Program code for the Laboratory 
Information System (LIS) software was rewritten to enable implementation of rules at three levels– 
general, provincial or facility. Studies assessing the expenditure since the implementation may be 
able to accurately estimate the national savings since the implementation.  
In South Africa, 82% of the population or approximately 45 million people, utilise the public health 
service which relies on the NHLS (21). The NHLS is currently experiencing a shortage in experienced 
pathologists. There are approximately 237 pathologists working within the NHLS (5.2 per million of 
the population).  In South Africa, pathologists have medical degrees unlike many other countries 
where academic laboratories are scientist-driven. Pathologists play a vital role in educating clinicians 
about the appropriate use of laboratory tests based on the clinical findings and this in effect leads to 
a decrease in costs. The savings which result from electronic gatekeeping could be potentially used 
to employ an additional 50 pathologists nationally and this could lead to even further decreases in 
healthcare expenditure. 
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Conclusion 
Laboratory medicine must continually strive to improve standards of healthcare while reducing 
inefficiency and reducing cost (1) while facing an increase in workload.  
This study has shown a decrease in test volumes and cost per inpatient day by the implementation 
of electronic gatekeeping. Electronic gatekeeping has therefore been shown to be an effective 
utilisation management tool.  
The use of ratios to apply the criteria nationally also showed substantial potential savings. 
Utilization management addresses the appropriateness of laboratory testing with a focus on quality, 
and electronic gatekeeping as a utilization management strategy is relatively easy to implement and 
manage when the savings are considered. The cost of downstream care and investigations was not 
assessed, and the potential for saving is therefore likely to be substantially more.  
The potential exists for greater savings with stricter rules relating to minimum-retest intervals. The 
NHLS has subsequently implemented a national electronic gatekeeping strategy using minimum 
retest intervals. Studies assessing the expenditure since the implementation may be able to 
accurately estimate the national savings since the implementation.   
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ix. Appendices: 
a. Supplementary data 
Table 1. Data from 2011 and 2012. Similar test numbers and cost.
Analyte 2008 2011 2012 
 Tests per 
inpatient 
day 
Cost per 
inpatient 
day 
Tests per 
inpatient 
day 
Cost per 
inpatient 
day 
Tests per 
inpatient day 
Cost per 
inpatient day 
Sodium 0.21 R5.55 0.25 R6.57 0.26 R6.89 
Potassium 0.21 R5.55 0.26 R6.91 0.29 R7.56 
Chloride 0.05 R0.91 0.004 R0.08 0.003 R0.05 
Urea 0.21 R5.56 0.24 R6.21 0.25 R6.69 
Creatinine 0.22 R5.72 0.26 R6.90 0.29 R7.49 
Total protein 0.09 R2.07 0.02 R0.47 0.03 R0.57 
Albumin 0.12 R4.05 0.06 R2.01 0.07 R2.27 
Total bilirubin 0.12 R3.59 0.06 R1.92 0.07 R2.05 
Direct bilirubin 0.10 R2.36 0.03 R0.79 0.04 R1.02 
ALT 0.13 R4.94 0.08 R3.09 0.08 R3.15 
AST 0.11 R4.46 0.06 R2.36 0.06 R2.47 
ALP 0.12 R4.62 0.06 R2.38 0.07 R2.66 
GGT 0.11 R4.52 0.06 R2.27 0.06 R2.38 
CRP 0.04 R3.17 0.01 R0.56 0.01 R0.98 
PCT 0.01 R1.71 0.002 R0.70 0.01 R2.06 
FBC 0.19 R9.45 0.18 R9.21 0.16 R8.12 
WCC 0.01 R0.18 0.01 R0.18 0.01 R0.20 
HbA1c 0.003 R0.26 0.0004 R0.03 0.002 R0.12 
Glucose 0.012 R0.33 0.004 R0.22 0.004 R0.09 
TSH 0.01 R1.88 0.01 R1.19 0.01 R1.30 
Free T4 0.01 R1.15 0.003 R0.35 0.002 R0.30 
Free T3 0.002 R0.29 0.0002 R0.03 0.0003 R0.04 
Ca 0.05 R1.26 0.05 R1.26 0.05 R1.25 
Mg 0.04 R1.14 0.05 R1.19 0.05 R1.21 
Phos 0.04 R1.13 0.04 R1.13 0.04 R1.14 
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 Ratio Absolute number of tests Cost USD Cost ZAR Cost-saving USD Cost-saving ZAR 
CRP   10.24 78.81 2 870 347 22 085 707 
Groote Schuur 0.08 (1.0) 14 542 148 945.90 1 146 055   
Hospital 2 1.9 13 500 138 273.20 1 063 935 64 330.33 494 985.80 
Hospital 3 2.0 12 700 130 079.30 1 000 887 65 363.20 502 933.30 
Hospital 4 2.7 20 201 206 908 1 592 041 130 558.20 1 004 572 
Hospital 5 2.7 29 594 30 311.40 2 332 303 192 489.40 1 481 098 
Hospital 6 3.8 32 136 329 151.80 2 532 638 241 843.60 1 860 851 
Hospital 7 4.8 93 003 952 579.80 7 329 566 752 877.50 5 792 970 
Hospital 8 5.6 81 402 833 757 6 415 292 684 871.80 5 269 704 
Hospital 9 6.1 48 542 497 189.60 3 825 595 420 698.90 3 237 042 
Hospital 10 6.5 36 613 375 007.30  2 885 471 317 313.90 2 441 552 
PCT   43.72 336.41 3 224 952  24 814 195 
Groote Schuur 0.004 (1.0) 790 34 539.70 265 763.90   
Hospital 2 12.7 4 971 217 338 1 672 294 200 153.90 1 540 072 
Hospital 3 10.5 4 174 182 492.20 1 404 175 165 145.20 1 270 700 
Hospital 4 0.5 216 9 443.80 72 664.56   
Hospital 5 0.0 1 43.72 336.41   
Hospital 6 32.8 15 080 659 315.50  5 073 063 639 219.80 4 918 438 
Hospital 7 4.1 3 834 167 627 1 289 796 126 237.60 971 327.70 
Hospital 8 12.4 7 492 327 559.10 2 520 384 301 055.80 2 316 455 
Hospital 9 43.4 15 734 687 909.20 5 293 075 672 067.80 5 171 184 
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Hospital 10 93.4 25 919 1 133 210 8 719 411 1 121 072 8 626 019 
Cl   2.44 18.75 1 955 233 15 044 418 
Groote Schuur 0.12 (1.0) 17 339 42 252.10 325 106.30   
Hospital 2 8.8 75 360 183 639.10  1 413 000 162 673.30 1 251 680 
Hospital 3 8.8 65 884  160 547.80 1 235 325 142 213.50 1 094 253 
Hospital 4 8.7 87 512  213 251.40 1 640 850 188 846.50 1 453 068 
Hospital 5 3.8 47 642  116 095.20  893 287.50 85 826.70 660 388.20 
Hospital 6 8.8 104 153    253 802.60 1 952 869 224 918.50 1 730 622 
Hospital 7 8.7 234 395  571 179.60 4 394 906 505 797.90 3 891 831 
Hospital 8 8.8 169 130 412 140.20 3 171 188 365 101.50 2 809 251 
Hospital 9 8.7 107 644  262 309.60 2 018 325 232 046.70 1 785 469 
Hospital 10 5.4 24 082  58 683.60 451 537.50 47 808.20 367 856.90 
Urea   3.41 26.27 983 507.70  7 567 539 
GSH 0.58 (1.0) 138 514 472 908.20 3 638 763   
Hospital 2 1.5 75 766 258 676.80 1 990 373 84 812 652 580.80 
Hospital 3 1.2 67 068 228 980.50 1 761 876 38 954.90 299 735.80 
Hospital 4 1.5 89 167 304 429.90 2 342 417 94 787.95 729 340.10 
Hospital 5 1.1 131 063 447 469.30 3 443 025 53 432.90 411 135.90 
Hospital 6 1.6 104 307 356 120.20 2 740 145 139 363.20 1 072 321 
Hospital 7 1.3 237 750 811 715.20 6 245 693 194 114.20 1 493 600 
Hospital 8 1.4 178 935 610 911.70 4 700 622 164 659.30 1 266 961 
Hospital 9 1.4 119 379 407 578.30 3 136 086 104 751.50 806 003.90 
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Hospital 10 1.6 82 490 281 633.60 2 167 012 108 631.80 835 861 
AST   5.11 39.34 382 118.30  2 940 186 
GSH 0.59 (1.0) 49 289 252 004 1 939 029   
Hospital 2 0.3 12 549 64 160.30 493 677.70   
Hospital 3 1.2 33 806 172 842.80 1 329 928 29 464.80 226 715.40 
Hospital 4 1.1 36 128 184 714.70 1 421 276 21 760.10 167 432 
Hospital 5 0.7 18 459 94 376.90 726 177.10   
Hospital 6 1.8 65 873 336 794.40 2 591 444 146 417.80 1 126 603 
Hospital 7 1.0 71 341 364 751.10 2 806 555   
Hospital 8 1.1 63 024 322 228.10 2 479 364 28 572.90 219 852.50 
Hospital 9 1.4 55 311 282 793.20 2 175 935 81 531.20 627 336.90 
Hospital 10 1.7 34 977 178 829.80 1 375 995 74 371.40 572 246.20 
TP   2.93 22.58 624 880.10  4 808 102 
GSH 0.24 (1.0) 19 714 57 852.45  445 142.10   
Hospital 2 4.1 53 733 157 684.20 1 213 291 119 239.50 917 481 
Hospital 3 3.1 33 133 97 231.70 748 143.10 65 394.65 503 175.20 
Hospital 4 2.9 35 085 102 960 792 219.30 67 148.45 516 669.60 
Hospital 5 0.8 8 594 25 219.80 194 052.50   
Hospital 6 4.5 65 556 192 379.80 1 480 254 149 770.30 1 152 398 
Hospital 7 2.1 60 162 176 550.60 1 358 458 93 133.70 716 611.30 
Hospital 8 2.6 57 152 167 717.50 1 290 492 102 068.40 785 359.10 
Hospital 9 0.4 11 241 32 987.70 253 821.80   
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Hospital 10 3.1 14 113 41 415.80 318 671.50 28 125.15 216 407.20 
HbA1c   9.61 73.96 961 627.50 7 399 184 
GSH 0.04 (0.1) 8 851.61  85 077  654 620   
Hospital 2 0.6 2 289 22 002.20 169 294.40 11 588.20  
Hospital 3 1.3 5 017 48 224.10 371 057.30 46 330.80 89 164.50 
Hospital 4 2.2 8 888 85 432.70 657 356.50 73 153.10 356 489.70 
Hospital 5 2.0 15 431 148 324.90 1 141 277 355 027 562 872.40 
Hospital 6 8.3 41 992 403 632.90 3 105 728 97 621.20 2 731 733 
Hospital 7 1.9 21 590 207 526 1 596 796 274 059.60 751 140.40 
Hospital 8 4.2 37 514 360 589.70 2 774 535 58 363.60 2 108 734 
Hospital 9 1.9 12 572 120 843.80 929 825.10 45 484 449 075 
Hospital 10 2.4 8 225 79 059.80 608 321 11 588.20 349 974.10 
T4   16.60 127.75 1 206 955  9 286 843 
GSH 0.38 (1.0) 9 597 159 338  1 226 017   
Hospital 2 1.3 1 16.60 
 
127.75 
 
3.90 29.90 
Hospital 3 2.1 3 059 50 788.27 390 787.30 26 371.65 202 915.10 
Hospital 4 2.2 11 008 182 764.70  1 406 272 99 829 768 128.50 
Hospital 5 0.8 9 344  155 137.50 1 193 696   
Hospital 6 2.4 70 982 1 178 507  9 067 951 676 086.20 5 202 104 
Hospital 7 1.2 13 041 216 518.40  1 665 988 38 415.20 295 583.70 
Hospital 8 1.9 16 938 281 219.90  2 163 830 129 703.60 997 996.40 
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Hospital 9 1.8 11 920 197 906.60  1 522 780 89 958.90 692 183 
Hospital 10 2.1 16 760 278 264.60  2 141 090 146 586.70 1 127 903 
T3   16.60  127.75 1 106 740  8 515 743 
GSH 0.03 (1.0) 769 12 767.63 98 239.75   
Hospital 2 - - - - - - 
Hospital 3 15.3 2 131 35 380.78 272 235.30 33 072.80 254 476.50 
Hospital 4 24.6 10 264 170 412.20  1 311 226 163 471.10 1 257 818 
Hospital 5 2.9 2 538 14 360.10  324 229.50 27 778.10 213 736.60 
Hospital 6 19.3 53 014 880 186.20  6 772 539 834 643.50 6 422 113 
Hospital 7 1.1 769 11 550.70 98 239.75 1 216.90 9 363.60 
Hospital 8 3.5 3 213 14 951.06  410 460.80 38 394 295 420.70 
Hospital 9 1.5 924 10 209.12  118 041 5 132 39 487.50 
Hospital 10 1.3 800 10 250.67  102 200 3 031.65 23 326.80 
T3   16.60  127.75   
GSH 0.08 (1.0) 769     
Hospital 2 - - - - - - 
Hospital 3 8.7 2 131     
Hospital 4 11.6 10 264     
Hospital 5 3.4 2 538     
Hospital 6 9.3 53 014     
Hospital 7 0.7 769     
Hospital 8 2.4 3 213     
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Hospital 9 1.0 924     
Hospital 10 0.6 800     
Mg   3.41 26.27 95 513.44 734 922.30 
GSH 0.91 (1.0) 30 913 105 541.80  812 084.50   
Hospital 2 1.1 39 983 136 508.10 1 050 353 11 895.10 91 526 
Hospital 3 1.1 10 901 37 217.70 286 369.30 3 549.60 27 312.30 
Hospital 4 1.1 9 324 31 833.60 244 941.50 2 073.20 15 952 
Hospital 5 1.0 40 593 138 590.80 1 066 378 3 381.90 26 021.50 
Hospital 6 1.1 49 505 169 017.70 1 300 496 18 881.70 145 284 
Hospital 7 1.1 70 340 240 151.60 1 847 832 18 816.20 144 780.30 
Hospital 8 1.1 86 313 294 685.90 2 267 443 21 046.30 161 939.80 
Hospital 9 1.0 38 658 131 984.40 38 658   
Hospital 10 1.1 38 745 132 281.40 1 017 831 15 869.40 122 106.30 
Total     13 411 873.96  103 196 838.80 
 
Table 2. Ratios of Groote Schuur Hospital and other national academic hospitals. Hospitals 2 – 10 are compared to GSH which is taken as the comparator with an assigned ratio of 1. 
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